Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, is developing a class of drugs for diseases that are not served by existing treatments. The company is headquartered in Cambridge, the United Kingdom.
| Revenue (TTM) | $61.20M |
| Gross Profit (TTM) | $-127.85M |
| EBITDA | $-200.81M |
| Operating Margin | -8674.00% |
| Return on Equity | -32.30% |
| Return on Assets | -17.90% |
| Revenue/Share (TTM) | $0.88 |
| Book Value | $7.31 |
| Price-to-Book | 0.54 |
| Price-to-Sales (TTM) | 4.57 |
| EV/Revenue | 21.22 |
| EV/EBITDA | -2.14 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -78.50% |
| Shares Outstanding | $50.37M |
| Float | $1.88M |
| % Insiders | 4.47% |
| % Institutions | 72.08% |
Volatility is currently contracting
Visa is set to acquire Israel-based fraud intelligence company BioCatch for $2.4 billion. The all-cash deal, announced Monday (Aug. 3) aims to complement Visa's cyber, fraud, risk and security solutions and help clients protect themselves and customers from a growing range of fraud-related threats.
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the first quarter ended March 31, 2026, and provided recent corporate updates. “The data we reported in the first quarter continues to provide further validation of the potential of our Bicycle technology to deliver oncology th.
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced an oral presentation and multiple poster presentations across five abstracts at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting, taking place May 29–June 2 in Chicago. Presentation Details: Title: Interim analysis results from.
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced updates from its EphA2 pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2026. “EphA2 is a potentially high value target that is widely expressed in cancer and has been considered undruggable following the failure of mu.
The mean of analysts' price targets for Bicycle Therapeutics (BCYC) points to a 137.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BCYC and any ticker you trade — then tracks every position and per-strategy win rate.
